Lonza Introduces Risk Assessment Platform for Biopharmaceuticals - - BioPharm International

ADVERTISEMENT

Lonza Introduces Risk Assessment Platform for Biopharmaceuticals


Early risk assessment has become a crucial factor in biopharmaceutical drug development programs. To address this growing market need, Lonza launched a Developability Assessment Platform that is designed to reduce attrition rates and improve the ranking of early drug candidates, according to a press release. The prediction tools include a suite of in silico-based services that assess candidates for fitness for large-scale manufacture (manufacturability) and immunogenicity profiles in humans (safety).

The manufacturability assessment service analyzes chemical degradation pathways and post-translational modifications, including deamidation, oxidation, and glycosylation, as well as potential physical stability issues, such as protein aggregation. The safety assessment service uses Lonza’s proprietary Epibase in silico screening tool to identify potential T-cell epitopes in target proteins that may trigger potential immune reactions in human studies.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pandemic Vaccine Facility Dedicated in Texas
September 19, 2014
GSK Fined in China Bribery Scandal
September 19, 2014
Guideline Delineates How to Implement GS1 Standards to Support DSCSA
September 19, 2014
GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
Author Guidelines

Click here